All In Biotech

Drug Trial Radar · NCT00394953

A Study of Mircera for the Maintenance Treatment of Anemia in Dialysis Patients

A Randomized, Controlled, Open Label, Multicenter, Parallel-group Study to Compare the Effect of Mircera With That of Darbepoetin Alfa, Administered Intravenously at Extended Dosing Intervals, for the Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Who Are on Hemodialysis

Last checked: Nov 20, 2026Latest source record: Jan 20, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 490 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

490

Actual

Start

Dec 2006

Primary completion

Nov 2008

Study completion Nov 2008

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Nov 2, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This 2 arm study will compare the efficacy and safety of Mircera and darbepoetin alfa, administered at extended dosing intervals, in the maintenance treatment of anemia in patients with chronic kidney disease (CKD) who are on hemodialysis. Eligible patients receiving once-weekly intravenous (IV) darbepoetin alfa maintenance treatment will be randomized to receive either intravenous Mircera once a month (at a starting dose of 120, 200 or 360 micrograms/month, depending on the weekly dose of darbepoetin alfa prior to start of study) or intravenous darbepoetin alfa every 2 weeks before switching to once monthly administration. The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.

Conditions

  • Anemia

Interventions

  • Darbepoetin alfaDrug

    As prescribed, iv.

  • methoxy polyethylene glycol-epoetin beta [Mircera]Drug

    120, 200 or 360 micrograms iv / month, starting dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Lesser Than or Equal to One Gram Per Deciliter Decrease in Average Hemoglobin From Baseline and Maintaining Average Hemoglobin Level Greater Than or Equal to 10.5 g/dL Over Evaluation PeriodTime frame: Baseline (Week -4 to Week -1) and Evaluation period (Weeks 50 to 53)

Locations

88 sites in 14 countries. Site status is shown where the registry gives one.

  • Site not named

    Adelaide, Australia

  • Site not named

    Clayton, Australia

  • Site not named

    Gosford, Australia

  • Site not named

    Parkville, Australia

  • Site not named

    Woolloongabba, Australia

  • Site not named

    Linz, Austria

  • Site not named

    Vienna, Austria

  • Site not named

    Vienna, Austria

  • Site not named

    Aalst, Belgium

  • Site not named

    Brussels, Belgium

  • Site not named

    Brussels, Belgium

  • Site not named

    Roeselare, Belgium

  • Site not named

    Calgary, Alberta, Canada

  • Site not named

    Hamilton, Ontario, Canada

  • Site not named

    Kitchener, Ontario, Canada

  • Site not named

    Mississauga, Ontario, Canada

  • Site not named

    Ottawa, Ontario, Canada

  • Site not named

    Toronto, Ontario, Canada

  • Site not named

    Greenfield Park, Quebec, Canada

  • Site not named

    Trois-Rivières, Quebec, Canada

  • Site not named

    Aalborg, Denmark

  • Site not named

    Hillerød, Denmark

  • Site not named

    Roskilde, Denmark

  • Site not named

    Tampere, Finland

  • Site not named

    Turku, Finland

  • Site not named

    Auch, France

  • Site not named

    Bordeaux, France

  • Site not named

    Boulogne, France

  • Site not named

    Castelnau-le-Lez, France

  • Site not named

    Cergy-Pontoise, France

  • Site not named

    Chamalières, France

  • Site not named

    Dijon, France

  • Site not named

    Fleury-Mérogis, France

  • Site not named

    Hérouville-Saint-Clair, France

  • Site not named

    La Tronche, France

  • Site not named

    Lyon, France

  • Site not named

    Montpellier, France

  • Site not named

    Nîmes, France

  • Site not named

    Paris, France

  • Site not named

    Paris, France

Showing 40 of 88 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.